Sector pending / Biological Products, Except Diagnostic SubstancesUpdated 2026-05-10 22:07 UTC

FRA/EX9 stock hub

FRA/EX9 has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

FRA/EX9is not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

10.3B

Frankfurt Stock Exchange

Market data

Live price

Current market quote for this ticker.

Current price

FRA/EX9

In the news

Latest news · FRA/EX9

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E12.5

P25 n/aP50 n/aP75 n/a

Trailing P/E14.2

P25 n/aP50 n/aP75 n/a

ROE41

P25 n/aP50 n/aP75 n/a

ROIC60.4

P25 n/aP50 n/aP75 n/a

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All FRA/EX9 market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

215

Groups with data

Currency

USD

Showing 215 of 215 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	United States
Country code	DE
Employees	1,077
Employees Change	-70%
Employees Change Percent	-6.1
Enterprise value	EUR 9.2B
Exchange	Frankfurt Stock Exchange
Financial currency	USD
First seen	2026-05-10
Industry	Biological Products, Except Diagnostic Substances
Last refreshed	2026-05-10
Market cap	EUR 10.3B
Price	EUR 39.06
Price currency	EUR
Rev Per Employee	1,912,965.04x
Sic	2836
Symbol	fra/EX9
Website	https://www.exelixis.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	7.03%
EV Earnings	12.75x
EV/EBIT	11.33x
EV/EBITDA	10.67x
EV/FCF	11.58x
EV/Sales	4.57x
FCF yield	7.74%
Forward P/E	12.46x
P/B ratio	6.13x
P/E ratio	14.23x
P/S ratio	4.99x
PE Ratio10 Y	62.12x
PE Ratio3 Y	26.51x
PE Ratio5 Y	28.94x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	40.29%
EBITDA Margin	41.5%
FCF margin	38.63%
Gross margin	96.44%
Gross Profit	EUR 2B
Gross Profit Growth	2.98%
Gross Profit Growth Q	10.18%
Gross Profit Growth3 Y	12.6%
Gross Profit Growth5 Y	18.26%
Net Income	EUR 722.8M
Net Income Growth	29.5%
Net Income Growth Q	31.86%
Net Income Growth3 Y	75.67%
Net Income Growth5 Y	66.69%
Pretax Margin	42.23%
Profit Margin	35.08%
Profit Per Employee	EUR 671,148
ROA	22.03
Roa5y	9.89
ROCE	43.07
ROE	40.99
Roe5y	17.29
ROIC	60.44
Roic5y	29.34

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	24.95%
Cagr15y	11.95%
Cagr1y	18.72%
Cagr20y	7.88%
Cagr3y	31.45%
Cagr5y	14.42%
EPS Growth	37.17
EPS Growth Q	43.64
EPS Growth3 Y	85.92
EPS Growth5 Y	71.26
FCF Growth	11.79%
FCF Growth Q	20.07%
FCF Growth3 Y	51.26%
FCF Growth5 Y	43.37%
OCF Growth	9.74%
OCF Growth Q	19.11%
OCF Growth10 Y	31.39%
OCF Growth3 Y	45.64%
OCF Growth5 Y	36.88%
Revenue Growth	3.33x
Revenue Growth Q	9.97x
Revenue Growth3 Y	12.6x
Revenue Growth5 Y	18.17x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	EUR 0.87
Assets	EUR 2.2B
Cash	EUR 674.1M
Current Assets	EUR 1B
Current Liabilities	EUR 314.6M
Debt	EUR 147M
Debt EBITDA	EUR 0.17
Debt Equity	EUR 0.09
Debt FCF	EUR 0.18
Equity	EUR 1.7B
Liabilities	EUR 570.5M
Long Term Assets	EUR 1.2B
Long Term Liabilities	EUR 256M
Net Cash	EUR 1.1B
Net Cash By Market Cap	EUR 10.6
Net Cash Growth	-14.13%
Net Debt EBITDA	EUR -1.27
Net Debt Equity	EUR -0.65
Net Debt FCF	EUR -1.37
Tangible Book Value	EUR 1.6B
Tangible Book Value Per Share	EUR 6.4

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	3.26
Inventory Turnover	3.28
Net Working Capital	EUR 52.4M
Quick ratio	3.01
Working Capital	EUR 726.5M
Working Capital Turnover	EUR 2.25

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	5.19%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	827.45%
1Y total return	18.71%
200-day SMA	33.36
3Y total return	127.2%
50-day SMA	36.97
50-day SMA vs 200-day SMA	50over200
5Y total return	96.11%
All Time High	53.5
All Time High Change	-27%
All Time High Date	2000-07-24
All Time Low	1.03
All Time Low Change	3,691.75%
All Time Low Date	2014-12-17
ATR	0.87
Ch YTD	8.64
High	39.06
High52	44.4
High52 Date	2025-06-23
High52ch	-12.04%
Low	39.06
Low52	29.41
Low52 Date	2025-10-21
Low52ch	32.8%
Ma50ch	5.64%
Price vs 200-day SMA	17.06%
RSI	56.63
RSI Monthly	67.75
RSI Weekly	63.6
Sharpe ratio	1.46x
Sortino ratio	2.65
Total Return	5.19%
Tr YTD	8.64
Tr15y	443.56%
Tr1m	3.81%
Tr1w	5.8%
Tr3m	10.05%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	EUR 830.2M
Operating Income Growth	17.52
Operating Income Growth Q	34.51
Operating Income Growth3 Y	86.71
Operating Income Growth5 Y	78.62
Operating margin	40.29

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	205,743,078%
Shares Insiders	1.91%
Shares Institutions	89.65%
Shares Qo Q	-3.27%
Shares Yo Y	-5.19%
Short Ratio	10.04

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	EUR 695.2M
Average Volume	73.1x
Bv Per Share	6.62
CAPEX	EUR -6.1M
Ch10y	827.5
Ch15y	443.6
Ch1m	3.81
Ch1w	5.8
Ch1y	18.71
Ch20y	355.7
Ch3m	10.05
Ch3y	127.2
Ch5y	96.11
Ch6m	13.2
Change	0.1%
Change From Open	0
Close	39.02
Days Gap	0.1
Depreciation Amortization	24,300,895
Earnings Date	2026-05-05
EBIT	EUR 830.2M
EBITDA	EUR 855M
EPS	EUR 2.62
F Score	5
FCF	EUR 795.9M
FCF EV Yield	8.64x
Financing CF	-981,681,259
Fiscal Year End	December
Founded	1,994
Goodwill	54,001,612
Graham Number	19.8429
Graham Upside	-49.19
Income Tax	EUR 147.3M
Investing CF	216,484,151
Is Primary Listing	0
Last Earnings Date	2026-05-05
Last Report Date	2026-03-31
Lynch Fair Value	EUR 68.62
Lynch Upside	75.71
Ma150	36.17
Ma150ch	7.98%
Ma20	38.16
Ma20ch	2.34%
Net CF	36,773,520
Open	39.06
P FCF Ratio	12.92
P OCF Ratio	12.82
Ppne	81,000,722.1
Price Date	2026-05-08
Price EBITDA	EUR 12.03
Ptbv Ratio	6.33
Relative Volume	0.71x
Revenue	2,060,263,344x
SBC By Revenue	4.89x
Share Based Comp	100,696,132
Tax By Revenue	7.15x
Tax Rate	16.92%
Tr20y	355.72%
Tr6m	13.2%
Z Score	12.52

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does FRA/EX9 pay a dividend?

Capital-return profile for this ticker.

Performance

FRA/EX9 stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns FRA/EX9?

Insider, institutional, and short-interest positioning.

Institutional ownership

+89.7%

Share of float held by funds and institutions

Insider ownership

+1.9%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

FRA/EX9 momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

56.6

Neutral momentum band

Price vs 200-day MA

+17.1%

50/200-day relationship not available

Beta (5Y)

n/a

Sensitivity to the broader market

Sharpe ratio

1.46

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About FRA/EX9

Hub-level FAQ points readers to the deeper analysis pages.

What is the current fra/EX9 stock rating?

fra/EX9 is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full fra/EX9 analysis?

The full report lives at /stocks/fra/EX9/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for fra/EX9?

The latest report frames fra/EX9 around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the fra/EX9 page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.